Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The safety of attenuated poxviruses in HIV-1-infected individuals is an important consideration in their application as vaccine vectors, first, because new HIV-1 infections may occur in vaccine trials involving persons at high risk of infection and secondly, therapeutic vaccinations are a potential means to enhance virus-specific immune responses once infection has occurred. We administered a candidate modified vaccinia virus Ankara-vectored HIV-1 vaccine, MVA.HIVA, by intradermal injection to 16 chronically infected adults during highly active antiretroviral therapy. Vaccinations were well tolerated and there were no serious adverse events. No breakthrough viraemia occurred after immunisations or throughout follow-up. These data confirm the safety of MVA.HIVA in HIV-1-infected individuals and provide support for further evaluation of MVA-vectored vaccines in prophylactic and therapeutic immunisation strategies.

Original publication




Journal article



Publication Date





3277 - 3283


AIDS Vaccines, Acquired Immunodeficiency Syndrome, Adult, Antiretroviral Therapy, Highly Active, CD4 Lymphocyte Count, CD8-Positive T-Lymphocytes, Epitopes, T-Lymphocyte, Female, Gene Products, gag, HIV Antigens, HIV Core Protein p24, HIV-1, Humans, Male, Middle Aged, Viral Load, Viral Proteins, gag Gene Products, Human Immunodeficiency Virus